Chester County News and Community Website
LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) granted equity awards covering 87,000 shares of company stock to four newly hired employees, using inducement incentives as the clinical-stage biotechnology company advances …
Savara Grants Equity Awards to New Hires Amid Growth Push Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) is restructuring its executive leadership team after Chief Financial and Administrative Officer Dave Lowrance stepped down for health-related reasons, placing Chief Operating Officer …
Savara Shifts Finance Leadership Ahead of Key Drug Milestone Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) reported new Phase 3 clinical trial data showing its experimental therapy molgramostim improved lung function and reduced disease-associated biomarkers in patients with autoimmune …
Savara Reports Phase 3 Biomarker Gains for Rare Lung Disease Read More LANGHORNE, PA — Savara (Nasdaq: SVRA) reported long-term Phase 3 trial data showing continued improvements in lung function and respiratory quality of life among patients receiving molgramostim for autoimmune pulmonary …
Savara Reports Long-Term Phase 3 Data Supporting Molgramostim Durability Read More LANGHORNE, PA — Savara (Nasdaq: SVRA) reported new Phase 3 clinical trial data showing patients treated with its experimental inhaled therapy molgramostim achieved greater improvements in exercise capacity than those …
Savara Reports Phase 3 Data Showing Exercise Gains in Rare Lung Disease Trial Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) advanced regulatory filings for its lead rare lung disease therapy MOLBREEVI while reporting a wider first-quarter loss as the company ramps up manufacturing …
Savara Advances MOLBREEVI Toward FDA Decision as Loss Widens Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) recently granted equity inducement awards to 24 newly hired employees on April 14, 2026, under its 2021 Inducement Equity Incentive Plan.
Savara Grants Equity Awards to 24 New Employees Read More LANGHORNE, PA — The U.S. Food and Drug Administration has extended the review period for Savara Inc.’s (Nasdaq: SVRA) biologics license application for molgramostim by three months, setting a new …
FDA Extends Review of Savara’s Molgramostim Application to November Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) will present new clinical data on its investigational therapy molgramostim at the ATS International Conference in Orlando, Florida, May 17–20, 2026, the company …
Savara to Present Molgramostim Data at ATS 2026 Conference Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) said the U.K.’s Medicines and Healthcare products Regulatory Agency recently accepted its marketing authorization application for MOLBREEVI to treat autoimmune pulmonary alveolar proteinosis, …
Savara Says UK Regulator Accepts MOLBREEVI Application Read More